Adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC) Strengthens leadership in […]
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) — The Providence Service Corporation (“Providence”, or the “Company”) (Nasdaq: PRSC) today announced […]